OBI Pharma Announces Its In-house COVID-19 Vaccine, BCVax, can induce potent antibodies to neutralize against all variants

OBI Pharma Inc. (TPEx: 4174) announced today research results in the past six-months of their new COVID-19 Vaccine. The vaccine, named BCVax, has been proven to induce potent antibodies against COVID-19, and shown to have neutralizing activity against many SARS-CoV-2 variants. OBI has filed patent application to USPTO yesterday. Dr. Ming-Tain Lai, CSO of OBI […]

This article is password protected.

To view the content, please enter your password in the field below